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Objectives: There is an important need to evaluate therapeutic approaches for osteoarthritis (OA) in
terms of cost-effectiveness as well as efﬁcacy.
Methods: The ESCEO expert working group met to discuss the epidemiological and economic evidence
that justiﬁes the increasing concern of the impact of this disease and reviewed the current state-of-the-
art in health economic studies in this ﬁeld.
Results: OA is a debilitating disease; it is increasing in frequency and is associated with a substantial and
growing burden on society, in terms of both burden of illness and cost of illness. Economic evaluations in this
ﬁeld are relatively rare, and those that do exist, show considerable heterogeneity of methodological approach
(such as indicated population, comparator, decision context and perspective, time horizon, modeling and
outcome measures used). This heterogeneity makes comparisons between studies problematic.r HS Journals, Inc.
ervices Research, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
ity.nl (M. Hiligsmann).
Open access under CC BY license.
M. Hiligsmann et al. / Seminars in Arthritis and Rheumatism 43 (2013) 303–313304Conclusions: Better adherence to guidelines for economic evaluations is needed. There was strong support
for the deﬁnition of a reference case and for what might constitute “standard optimal care” in terms of best
clinical practice, for the control arms of interventional studies.
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Osteoarthritis (OA) is a common chronic joint disease that most
frequently affects the knee, hand, and/or hip. The disease generally
develops progressively over a number of years before potentially
becoming “a painful problem,” potentially leading to disability and
social isolation. It has high prevalence in the population older than
65 years, and the prevalence in younger age groups appears to be
on the increase [1,2]. Severe cases are increasingly referred for
total joint replacement [3].
As a result of this trend toward disability with all its conse-
quences, the economic burden of OA is high [4], in terms of both
direct health-related costs and indirect costs. The treatments are,
as yet, ineffective in limiting the progression of the disease and
most are focused on symptom modiﬁcation, particularly pain
control. Some non-pharmaceutical therapies try to promote life-
style changes which may help to maintain functional performance
longer [5]. It is anticipated that the future will bring disease-
modifying treatments, but it is likely that these will be expensive
and ineffective in some patients. It is therefore vital that the costs
and the impact on the quality of life (QoL) of the disease are
understood and that the cost-effectiveness of treatments can be
examined and compared in a methodical fashion allowing the
rational allocation of limited healthcare resources.
It was against this background that the European Society for
Clinical and Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) held an expert working group meeting in 2012 to present
the current state-of-the-art in health economics investigations in
this ﬁeld and to discuss what still needs to be done to reach this
goal. This paper was prepared on the basis of the presentations
and discussions surrounding that meeting.Diagnosis of OA
The diagnosis of OA is usually based on a combination of
clinical features and where needed radiographic conﬁrmation
(referred to as symptomatic OA) [1]. While the diagnosis may be
made on radiographic features alone, it is frequently observed that
about half of the persons identiﬁed in this way will have no related
symptoms or disability. Thus, the clinical relevance of certain
radiographic features is not entirely clear [6], but this approach
has relevance in epidemiological studies to deﬁne the population.
The most widely used criteria for diagnosing OA are those of the
American College of Rheumatology [7,8], and for a recent review
and discussion, the reader is directed to Bijlsma et al. [9] and
Nelson and Jordan [10], respectively.
The natural history of the disease is variable between patients
and between joints [11]. In many cases, the condition remains
stable for many years, while in others, the progression to severe
disability may take less than 1 year. There remains much uncer-
tainty concerning the contributory factors to disease progression,
which to some extent, appear joint speciﬁc [11] and genetic [12].
The burden of OA
The burden of musculoskeletal diseases on global health is
considerable. The recently published Global Burden of Disease
study [13] estimated that musculoskeletal diseases wereresponsible for almost 166 million years lived with disability
(YLDs) in 2010 (second only to mental and behavioral disorders
at 176 million YLDs). Within this grouping, osteoarthritis accounts
for slightly over 17 million YLDs in 2010, an increase of 64% over
the period 1990–2010 (set against a 40% growth for musculoske-
letal diseases as a whole).
Total joint arthroplasty
The indication for total joint arthroplasty (TJA) may be seen as
the end stage of OA (for the knee and hip) [14]. Although the rates
of TJA are highly variable among different countries with, amongst
OECD countries, a 36-fold difference in the rate of hip replacements
and a 70-fold difference in knee replacements, there is a steadily
increasing in demand in recent years [15]. In a retrospective
epidemiological study over the period 2001–2005, Piscitelli et al.
[16] collected data on the costs associated with joint arthroplasty in
Italy. For knee replacements in the male population, the annual
change in the number of joint arthroplasty was þ16.6% and in the
female population was þ12.4%. The overall incidence in 2005 was
99.9/100,000. For hip replacements (THA), the annual change was
þ5.8% in the male population and þ3.6% in the female population.
The overall incidence in 2005 was 94.4/100,000. Approximately 30%
of hip arthroplasty and 20% of knee arthroplasty were performed
annually in patients older than 65 years, impacting the workforce.
For 2005, it was estimated that over a million working days were
lost in Italy due to joint arthroplasty.
In a recent Finnish study [2], the changes in the incidence of
unicondylar knee arthroplasty (UKA) and total knee arthroplasty
(TKA) were assessed between 1980 and 2006. The annual cumu-
lative incidence of UKA and TKA has increased rapidly among 30–
59-year-olds. For UKA, the incidence increased from 0.2 to 10 per
100,000 inhabitants, and for TKA, the incidence increased from
0.5 to 65 per 100,000 inhabitants. The incidence of both interven-
tions was higher in women than in men. Most of the increase
occurred among patients in the older age group (50–59 years) than
in younger ones (30–39 and 40–49 years). On time–frequency plots,
the growth trajectories of TKA for men and women overall and TKA
for the older age group appear as exponentials. Nevertheless, an
increased demand for TJA by the “baby-boom” generation seems to
be sustained, and some estimates suggested that the volume in the
USA could expand by 17 times from that in 2006 [17]. A number of
reasons seem to underlie this change, including a more active
lifestyle when younger (therefore more joint injuries), increasing
longevity, increasing expectations of active life at older ages, and
greater incidence of obesity. It is unlikely however that these
hypothetical projections will be attained because of the increasing
pressure on healthcare costs and surgical workforce issues.
While there may be rather different criteria used for surgical
intervention in different countries, there appears to be an increas-
ing demand for joint arthroplasty in westernized populations that
are living longer and perhaps having greater expectations of more
active lifestyles in later age.
The impact of OA on quality of life
The burden of illness in OA at the individual level has been
investigated recently by Tarride et al. [18], who compared in a
cross-sectional study of Canadian health records the self-reported
health status and health-related quality of life (HR-QoL) in
OA patients vs. matched controls (matched by age, sex, and
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worse perceived health status than controls, with 34.8% reporting
a status of poor or fair vs. 18.5% of controls. OA patients also had a
lower HR-QoL (mean: 0.68 vs. 0.84 on Health Utility Index 3 score;
p o 0.0001). Similar differences were found in the analyses by
subgroups according to age, sex, obesity, and number of medical
conditions. The study also reported that comorbidities were
relatively more frequent in the OA patients, with 52.1% having
4 or more comorbid conditions vs. 26.9% in controls. Particularly
prevalent among OA patients were back problems [adjusted odds
ratio (adj OR) ¼ 2.5], stomach/intestinal ulcers (adj OR ¼ 3.7),
bowel disorders (adj OR ¼ 3.0), ﬁbromyalgia (adj OR ¼ 3.4), and
chronic fatigue syndrome (adj OR ¼ 3.2). It is not clear to what
extent these conditions are a consequence of OA, or its treatment,
or whether there is some underlying predisposition to medical
conditions that may also predispose to OA.
Losina et al. [19], starting with US census and obesity data for
persons aged 50–84 years, used a mathematical model to estimate
the quality-adjusted life year (QALY) losses in subgroups according
to obesity and knee OA. The total losses per person ranged from
1.857 years in non-obese persons with OA to 3.501 years in obese
persons with OA, resulting in an overall 86.0 million quality-
adjusted life years lost. Thus, OA seems to be linked to a consid-
erable decline in overall health.
In patients with severe OA, total joint replacement can improve
HR-QoL. This has been shown in short-term follow-up studies (e.g.,
[20]) and more recently in a long-term follow-up study [21]. In the
latter, consecutive patients who had just undergone an OA-related
TJA (hip or knee) were recruited and assessed for HR-QoL at
various intervals up to 7 years. In the 39 subjects who completed
the full follow-up period, the more marked improvements in both
SF-36 and WOMAC scores were seen at 6 months and at 7 years.
The authors concluded that QoL improvements are therefore
maintained over the long-term. Studies that have estimated costs
and outcome over the patient's projected lifetime using modeling
techniques [22] (in TKA) or over 5 years in a trial-based health
economic study [23] (in THA) have conﬁrmed the long-term
beneﬁts and cost-effectiveness of TJA in a wide variety of patients.
A greater incidence of death in OA patients, which had been
suggested in a review of clinical studies [24], has recently been
conﬁrmed by Nuesch et al. [25] in a retrospective epidemiological
study using general practice data from the south of England. This
research found that the all-cause mortality risk was greater in
individuals with symptomatic OA (knee or hip) with radiological
conﬁrmation (n ¼ 1163; aged Z35 years) than in the general
population (standardized mortality ratio ¼ 1.55). All disease-
speciﬁc causes contributed to the effect but it was mostly driven
by cardiovascular- and dementia-associated mortality. Once again,
it was not clear to what extent OA is related to these events or
whether there is some underlying predisposition.Costs associated with OA
The economic cost of OA is considerable [26]. Whether one
examines just the direct healthcare costs (hospital admissions,
medical examinations, drug therapy, etc.) or includes indirect costs
(e.g., losses in productivity resulting from absence from work), the
total costs relating to the treatment of OA are very high—estimated
at between 1% and 2.5% of the gross domestic product (GDP) for
westernized countries [27].
The direct costs of OA treatment are mostly driven by the cost
of surgery for TJA. In Great Britain, this was estimated to account
for 85% of the total direct costs of just over £1 billion in 2010 [28].
It was noted that while there was no national tariff for joint
replacement in the UK (they vary between healthcare trusts), the
ﬁnal cost was mostly dependent on the length of stay in hospital.In USA, hospital prices can vary considerably and in a very recent
study [29] that requested a “bundled price” (hospital plus physi-
cian fee) for THA, the researchers received fee estimates ranging
from $11,100 to $125,798. This study also noted that the majority
of hospitals were reluctant (unable or unwilling) to quote a
bundled fee. The total direct cost attributed to joint replacement
in the USA in 2009 was estimated to be $42 billion [30]. Costs that
must be integrated into these analyses are those associated with
post-surgical rehabilitation, costs that tend to be higher in older
patients for strategies with varying effectiveness [31,32]. While the
cost-effectiveness of TJA is not further discussed in this report, the
reader is directed to the following references of interest [33–35].
The healthcare costs for OA sufferers are considerably higher
than that for age-matched controls. In a 1997 cohort analysis of
Olmsted County data, Gabriel et al. [36] estimated that the direct
annual medical costs for OA patients (which included costs for
concomitant conditions) were $2655 (median $664) vs. $1688
(median $232) in controls—a strongly statistically signiﬁcant
difference (p o 0.0001 following adjustment for age and sex).
Other studies of the same period also found that OA patients
incurred markedly higher healthcare costs than non-affected
individuals [37,38]. More recently, in the pharmacoepidemiolog-
ical study by Tarride et al. [18] (mentioned above), the healthcare
costs to OA patients (i.e., for physician services, outpatient proce-
dures, and hospitalizations) were also noted to be about twice, per
person per year, than that of the non-OA controls (Canadian $2233
vs. $1033). This conclusion was not dependent on age group
(o65/Z65 years) but was more pronounced in men (OA patients
incurred 3.2 times the cost of controls) and in obese individuals
(3.1 times cost of controls). This study did not include drug costs
nor the costs associated with non-physician healthcare providers
or indirect costs, so the total costs to patients could be even higher.
In another recent cohort of OA sufferers in active employment, the
economic burden of the disease signiﬁcantly correlated with self-
rated disease severity [39].
The indirect costs of OA are driven mainly by the loss of
productivity due to absenteeism from paid work. These costs,
along with direct costs, are usually included in economic studies of
disease burden (termed societal costs). In the British study
discussed above, the estimated cost due to lost economic produc-
tion for OA was £3.2 billion in 2002 [28]. The study also estimated
that £258 million of indirect costs could be attributed to com-
munity and social services involvement. In a recent Dutch study,
patients with mild to moderate OA (of at least 6 months duration,
with conservative treatment and in paid employment) had mean
lost productivity costs of €722 (median €217) per patient per
month [40].
As joint arthroplasty has been increasing in recent years
(including in younger patients), thereby pushing up direct health-
care costs, it seems reasonable to assume that total costs associ-
ated with OA to society are rising fast. Piscitelli et al. [16] estimated
that the costs of TJA in Italy increased by 46% over the period
2001–2005; Chen and colleagues estimated the costs of TJA in the
UK increased by 66% over the period 2000–2010. Additionally,
Kurtz et al. [17] noted that there is greater demand for “premium”
implant technologies that are longer lasting, but more expensive
amongst the younger TJA candidates. The costs are therefore set to
increase for the foreseeable future.Therapeutic options in OA
Evidence-based guidelines for OA treatment have been pub-
lished under the auspices of the European League Against Rheu-
matism (EULAR) [41,42], Osteoarthritis Research Society
International (OARSI) [43], the National Institute for Health and
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College of Rheumatology (ACR) [45].
NICE groups the therapeutic options into 3 concentric rings,
based on the weight of evidence and the relative safety for the
patient (see Fig.). Starting in the center, the recommendations are
that all persons with OA should receive advice concerning
strengthening exercises, aerobic ﬁtness training, and weight loss
(where appropriate). The next ring of treatment strategies includes
the relatively safe pharmaceutical options of paracetamol and
topical non-steroidal anti-inﬂammatory drugs (NSAIDs), while
the outer ring proposes oral NSAIDs and adjunctive treatments, a
variety of less well-proven methods for symptom relief. The ﬁnal
option of joint arthroplasty is also included in the outer ring. The
OARSI and ACR guidelines add acupuncture to these adjunctive
treatments for pain relief.
All these therapies aim to reduce joint pain and stiffness and
thereby maintain or improve functional capacity.
The existing treatment options may therefore be grouped
as those which have a non-pharmacological approach and
those which have a pharmacological approach. From a stand-
point of health economics (HE) analysis, such a division makes
intuitive sense.The health economic evaluation
The economic evaluations of healthcare provide essential
information with which to guide efﬁcient resource allocation. In
many countries now, there is also a formal requirement for
economic evaluations to be included in the market authorization
dossier for a new pharmaceutical product or medical device
(particularly for reimbursement purposes) [46]. These economic
evaluations are often considered as the “fourth hurdle” of drug/
device approval, after efﬁcacy, safety, and quality [47].
There are 4 possible types of full economic evaluation, i.e. the
comparative analysis between 2 or more health technologies in
terms of costs and effects [48]Fig.
(NICCost-minimization analysis: where therapies are compared on
their costs only and there is no difference in effect (outcome)—
which is rather rare. Cost-effectiveness analysis: where therapies are compared on
their costs and outcomes, based on natural units (WOMAC
score, pain, quality of life, life years, etc.).Acupuncture
added by OARSI & ACR
Therapeutic options in OA grouped according to weight of evidence and the rela
E, 2008).tiveCost–utility analysis: where therapies are compared on their
costs and outcomes, based on their utility (the quality of living
adjusted by a value given by society) QALYs. Cost–beneﬁt analysis: where therapies are compared on their
costs and outcomes, based on effects in monetary terms (net
beneﬁt). The practical difﬁculties of measurement and valuing
health beneﬁts have limited the use of this type of analysis in
healthcare.
All 4 types therefore add-up to the costs similarly, but then
differ in how the patient outcomes are approached.
Costs
The cost items that may be included are given by the “per-
spective” of the analysis. Multiple perspectives exist, including the
societal perspective (the broadest view), which includes all direct
costs and indirect costs resulting from the condition and its
treatment; this perspective is theoretically preferred. However,
most local guidelines require the adoption of the decision maker
or healthcare payer perspective, which includes only the direct
medical costs. Other perspectives can be that of the patient, an
employer, or department budget [49]. Whichever approach is
adopted, it is recommended that the cost items should be
individually enumerated to facilitate comparisons between studies
[49].
Outcomes
The clinical outcomes of OA are pain, functional disability, and
mortality; the patient's global assessment is also frequently
identiﬁed as a “core” variable in clinical trials [50]. With the
exception of mortality, these outcomes are most often captured in
a HR-QoL questionnaire, which might be generic or disease
speciﬁc, but they can be scored using stand-alone tools for each
variable separately. Mortality is often not measured as an outcome
parameter since most clinical studies are of relatively short
duration (most being concerned with pain control), but for health
economic studies, it is considered important to be able to model
the lifetime costs and outcomes.
The QoL tools can be generic or speciﬁc to diseases. Generic
instruments include EQ-5D, SF-36, or Health Utility Index and can
be used in any intervention and disease [51]. Disease-speciﬁcsafety for the patient, with the ﬁrst options/recommendations at the center
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sensitivity to the clinical condition under consideration, but they
do not allow comparison with other disease areas.
To demonstrate treatment effect, the results of such tools are usually
summarized as means by treatment group to demonstrate treatment
effect, but some experts have argued for the adoption of response
thresholds, either on a composite outcome or pain alone [52,53].
A major factor for the patients who require long-term use of
oral NSAIDs is the avoidance of serious gastrointestinal adverse
events, such as ulcers, perforation, obstruction, or bleeding [54].
The most widely used type of health economic analysis is the
cost–utility analysis since it allows comparisons of different dis-
eases with different clinical outcomes. The outcome measure used
in cost–utility analyses is the QALY, a product of life expectancy
and QoL or, in other words, the remaining years of life and the
utility of those years. While these factors are clearly dependent on
the age of the individual, other concomitant health problems, and
prevailing QoL, the average indicators by age group are possible to
calculate. The QALY approach has been endorsed by the OMERACT
expert group [55].
Conducting an economic evaluation
The costs of an intervention and its associated outcomes can be
recorded (or estimated) by 2 different approaches: either a clinical
trial-based evaluation or by decision analytic modeling. Trial-
based evaluations of a type known as “explanatory trials” are
particularly found in the earlier stages of drug's lifecycle. In these
studies, the treated population is rigorously selected and homoge-
neous (and therefore a high internal validity). More frequently
encountered, however, are “pragmatic trials,” where patients are
treated in a “real-world,” clinical practice setting. Such studies
have a high external validity, i.e. in tune with real clinical practice,
but the internal validity (particularly randomization and treatment
blinding) can be strongly compromised.
The modeling studies use initial values obtained from clinical
trials, and then mathematical models to synthesize all down-
stream information regarding treatment process, costs, and out-
comes. They therefore provide a version of reality, which may be
simpliﬁed or complex but must remain credible. The preferred
modeling methods include decision trees, health-state transition
models (Markov), and discrete-event simulations.
The pros and cons of these economic approaches have been
extensively discussed [56–58].
Incremental cost-effectiveness ratio and willingness-to-pay
Pharmaceutical treatments or therapeutic procedures can
therefore be compared, against “standard care” or a therapy of
established cost-effectiveness, using the observed costs and out-
comes. While many HE trials compare just 2 treatments, it may be
that no single comparator is appropriate and more than one
should be included. Torrance has advocated that a new drug or
treatment should be compared to “all feasible alternative treat-
ments at all levels of intensity,” while admitting that such an
approach is usually impractical [59].
To compare 2 treatments based on their cost per QALY, the
incremental cost-effectiveness (or utility) ratio (ICER) is calculated.
This is deﬁned as the difference between the costs of 2 interven-
tions (A and B) divided by their difference in terms of effectiveness.
ðCostACOSTBÞ
ðQALYAQALYBÞ
¼ ICER
If an ICER is below an arbitrary threshold of “willingness-to-pay”
(per effectiveness unit), then the new intervention (as opposed to
the reference) is economically sound and should be adopted.The willingness-to-pay (WTP) for a treatment is a theoretical
value that is put on a treatment's effectiveness (i.e., per QALY). In
the UK, this is usually taken to be about £30 000 per QALY,
although NICE (who performs the economic analyses) has stated
that it does not put a threshold as to what constitutes an
unacceptable price, emphasizing that above this threshold the
justiﬁcation needs to be increasingly strong [60].
Most other countries have no generally accepted or recom-
mended thresholds for cost-effectiveness, or even a formal accept-
ation of the QALY as an economic construct. Nevertheless, the ICER
of new therapies does indeed inﬂuence the probability of which
they are reimbursed [61]. Therapies with low ICERs have relatively
high probabilities of being reimbursed whereas those with high
ICERs do not.
The World Health Organization (WHO) has suggested a cost-
effectiveness threshold based on evaluating each disability-
adjusted life-year (DALY) as 3 times the gross domestic product
(GDP) per capita [62], where a DALY is the sum of the expected
number of years of life lost (due to the disease) plus the expected
number of years lived with disability (due to the disease). On this
basis, a willingness-to-pay of 2-times the GDP per capita was
recommended and used to deﬁne intervention thresholds in
osteoporosis [63].Non-pharmacological treatments for osteoarthritis: Are they
value for money?
While the importance of maintaining physical activity is well-
recognized [64], the targets proposed in guidelines are frequently
unmet [65–68]. In part, this is because the percentage of GPs who
actually advise their OA patients to exercise or refer them for
physical therapy can be very low, with rates varying between 6%
and 63% [65]. This may be due to the inherent conﬂict in the
recommendation: exercise is beneﬁcial but maintaining adherence
is often difﬁcult. Specialized pain reduction techniques and life-
style modiﬁcations may be beneﬁcial in this respect, but they
require additional resources and health expenditure to be put in
place. So far, there is limited evidence that such non-pharmaco-
logic, non-surgical interventions in OA are cost-effective. Hence,
the recent study by Pinto et al. [69] that attempted to answer the
question: “do these interventions represent good value for
money?”
Their approach was to search electronic databases for all
randomized controlled trials (RCTs) or quasi-RCTs that speciﬁed
hip or knee OA and were published before October 1, 2010.
Excluded were studies on chronic knee pain (modeling studies
were also excluded since they are virtually non-existent in this
ﬁeld). The studies were assessed for the quality of economic
reporting using the QHES (Quality of Health Economic Studies)
instrument [70] and classiﬁed as either “high” quality (Z75
points) or “low” quality (o75 points). The studies were also
assessed for their “risk of bias” using an internal validity checklist
developed by Cochrane Back Review Group [71] and classiﬁed as
having either a high risk (o6 items satisﬁed) or low risk (Z6
items satisﬁed). The costs were converted to US$ (as valued in
2008), and where multiple costs were captured, the societal costs
were reported. The primary health outcome reported was the
QALY, and the WTP threshold was $50,000. They assessed 11
studies that investigated the health economics of exercise, acu-
puncture, rehabilitation, and lifestyle change.
Table 1 presents a selection of the included studies with the
summary details and outcome measures.
Most of the 11 studies in the review were identiﬁed as being
pragmatic (“real-world”) trials, but designed (or reported) in a way
that raised concern of possible bias. In no study was the outcome
Table 1
Summary details of a selection of the studies reviewed by Pinto et al. [69]
Type and reference Participants and indication (Payer
perspective)
Intervention (duration) total study duration Primary health outcome Result (relative to control)
Exercise programs
Richardson
et al. [72] (UK)
214 Patients; knee OA (NHS and
social services)
Physiotherapist-led classes þ home exercise
vs. home exercise alone (8 wk) 1 yr
Locomotor function (signiﬁcantly improved)
Costs were 1% lower in intervention gp and mean QALY/
person doubled (cost saving)
Cochrane et al.
[73] (UK)
312 Patients; hip and/or knee
OA; (Societal)
Instructor-led water exercises (n r 84)
vs. usual care (1 yr) 1.5 yr
WOMAC pain subscore (signiﬁcantly improved)
Costs were 25% lower and incremental QALY gain
reported (cost saving)
Acupuncture
Reinhold et al.
[74] (Germany)
489 Patients; hip and/or knee
OA; (Societal)
10–15 acupuncture sessions over vs.
delayed acupuncture trt (3 mo)
WOMAC index (signiﬁcantly improved)
Costs were almost 9-fold higher, but incremental QALY
gain reported. Incremental cost per QALY gained ¼
$25,707 (good value for money)
Rehabilitation programs
Coupé et al.
[75] (the
Netherlands)
200 Patients; hip and/or knee
OA; (Societal)
18 sessions of behavioral-graded activity
(BGA)a vs. standard physiotherapy
(12 wk) 1 yr
WOMAC pain subscore and pain VAS (NS difference over
short and long-term)
Costs were 24% lower, but at 1 yr QALYs were lost for a
saving of $63,019/QALY lost (poor value for money)
Hurley et al.
[76] (UK)
418 Patients; knee pain (mild-
severe); 3-arm (NHS and
social services)
12 sessions of ESCAPE programb (either
individual or grp) vs. usual care (6 wk)
7.5 mo
Responders on WOMAC functional subscore (i.e. Z15%
improvement): (sig. improved for both rehab arms vs.
usual care; nd not sig diff from each other
Costs increased 2.5 fold for individual sessions and
1.6 fold for groups; QALY loss and ICER dominated by
usual care (poor value for money)
Jessep et al.
[77] (UK)
64 Patients; knee pain (mild-
severe) (unspeciﬁed)
10 sessions of modiﬁed ESCAPE programb
vs. “usual physical therapy” (5 wk) 1 yr
WOMAC function subscore (NS difference between arms
at 12 mo)
Costs were 45% lower and incremental QALY gain
reported (good value for money)
Lifestyle
Lord et al. [78] 170 Patients; knee OA (Societal,
NHS, and individual)
Nurse-led patient education program vs.
usual care (4 wk) 1 yr
WOMAC index (NS for all subscales) Cost increases to
$659 (p o 0.001), QALY increases to 0.001
Costs increased 3.2 fold for no QALY change; ICER
dominated by usual care (poor value for money)
Patel et al. [79] 812 Patients; hip and/or knee
OA (health and social services
and Societal)
6 sessions of self-management program plus
booklet vs. education booklet alone (6 wk)
1 yr
SF-36 physical and mental health subscores (NS
difference at 1 yr)
Healthcare costs increased 1.6 fold at 1 yr; societal costs
were 3% lower. A slight QALYs loss was reported: a
saving of $4400/QALY lost (poor value for money)
OA, osteoarthritis; UK, United Kingdom; wk, week; mo, month; yr, year; NHS, National health service; vs., versus; trt, treatment; sig, signiﬁcant; NS, non-signiﬁcant.
a BGA: A process of encouraging increasing levels of activity via long- and short-term goal setting (operant conditioning) & integrating these activities into lifestyle;
provided by trained physiotherapists.
b ESCAPE ¼ Enabling Self-management and Coping with Arthritic Knee Pain through Exercise, a rehabilitation program integrating exercise, self-management, and
active coping strategies.
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reach the minimal threshold on the internal validity checklist. Only
5 studies satisﬁed the quality threshold of the QHES.
The review noted that in such economic evaluations, much of
the interpretation depends on the comparator used and whether it
has known cost-effectiveness and approval in the clinical setting
(disease and population under investigation). If this is the case,
then the new treatment may be tested and the overall efﬁciency of
healthcare spending compared.
The review also criticized that only one of the studies [80]
included a clinical outcome measure (% responders) that has
been recommended by OMERACT-OARSI for use in evaluations of
treatments for OA, although another study [76] did use the
percentage of responder patients on their improvement according
to physical function [52]. Also that, although most studies used the
WOMAC scale as an outcome measure, this was often expressed
only as one or other of the subscales and less frequently as the
total score.
An interesting outcome scenario was observed for the study of
behavioral-graded activity vs. a standard physiotherapy program.
The BGA program had lower costs but also QALY losses, so that the
ICER, with a saving of $63,000 per QALY lost, was situated in the
south-west (lower left) quadrant of the cost-effectiveness plane.
With a willingness-to-pay threshold estimate at $50,000, thisintervention would seem to be acceptable. However, the review
pointed out that the value which society is willing to pay for a
QALY gain is not necessarily the same as what will be accepted for
QALY loss, thus breaking the symmetry of the cost–beneﬁt
relationship [81,82]. In this case, a greater WTP threshold in the
lower left quadrant is appropriate, and this intervention should be
rejected. It might be noted that the authors of the original research
concluded that BGA yielded “similar” results to usual care and
therefore an acceptable alternative.
Previous reviews [5,83] of exercise programs for the manage-
ment of osteoarthritis (OA) of the knee have concluded on their
utility, and the Ottawa Panel [84] concluded that for obese/over-
weight OA patients, an intervention comprising physical activity
with diet produced the most beneﬁcial results. The most cost-
effective method to establish an effective exercise habit over the
long-term however remains elusive.
The points for future research indicated by this review are the
potential cost savings of employing non-healthcare professionals
for the exercise training programs; that studies of training pro-
grams should try to establish a dose effect on outcome measures
(as has been recently shown for physical activity levels [64]); the
need for longer and perhaps standardized time horizons (e.g.,
3 years); the possible effects of exercise on structural aspects of
the arthritic joint; and the interest of trying to quantify
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of exercise on pain relief to estimate how weight may directly
impact joint pain.Pharmacological treatments for osteoarthritis: Are they value
for money?
Previous systematic reviews have examined the cost-
effectiveness of cyclooxygenase-2 (COX-2)-selective non-steroidal
anti-inﬂammatory drugs (NSAIDs), including the ones by Maetzel
et al. [85] and more recently Chen and colleagues. Other reviews
have examined glucosamine and chondroitin supplements [86].
The Chen et al. review is particularly notable for its highly detailed
approach, with discussions of modeling methods and cost items.
For the purposes of the expert group meeting, a review was
made of full economic evaluations that have compared the costs
and outcomes of a least 2 pharmacological interventions and
published between 2003 and the end of September 2012. A search
was made of PubMed/Medline-referenced English language articles
using the key words (and Boolean operators): [osteoarthritis] AND
[cost-effectiveness, cost–utility, economic, cost]. Two reviewers
(M. Hiligsmann and J. Severens) independently applied these
criteria to identify citations during title and abstract screening.
A total of 16 studies that satisﬁed the inclusion criteria were
included in our review. These are presented in Table 2 with the
summary details, outcome measures, and results.
A total of 10 studies investigated COX-2-selective NSAIDs,
comparing them most frequently with a traditional NSAIDs (diclo-
fenac, ibuprofen, and naproxen) or high-dose acetaminophen. The
effects of various gastroprotective agents, such as proton pump
inhibitors (PPIs), histamine H2 receptor antagonists (H2RA), and
misoprostol, were also tested. One study examined the semi-
synthetic opioid analgesic oxycodone in 2 formulations. Three
studies examined oral doses of proteoglycan precursors, glucos-
amine (sulfate or hydrochloride), and chondroitin sulfate (which
may help repair joint cartilage).
A variety of patient groups were studied, with in some cases a
mixed population of OA and rheumatoid arthritis sufferers. Sub-
groups of patients included those who did not respond to acet-
aminophen; those who did not respond to acetaminophen and at
high risk of developing an adverse gastrointestinal event; those at
high risk of an upper gastrointestinal event; and elderly patients.
The investigators used different outcome measures, including
intermediary clinical outcomes, such as the number of serious gastro-
intestinal disorders or the number patients without side effects, and
generic outcome measures, such as years of life saved and QALYs.
Only one study [87] speciﬁcally examined the incidence of
serious CV event (myocardial infarction, stroke, and CV death) risk.
The studies were found to constitute a very heterogeneous
ensemble, making comparisons of the results between the studies
problematic.
The studies were performed in several different countries with
quite diverse public health systems including Canada, the UK, the
USA, Taiwan, Australia, Germany, Mexico, the Netherlands, and
Belgium. Various analytical models were used including decision
tree analysis, Markov model, discrete-event simulation, simulation
model, and trial-based economic evaluation. The time horizon of
the analysis varied from 4 months to lifetime.
Because of the large heterogeneity observed in the treatment
comparisons and methodologies, few ﬁrm conclusions could be
reached. In common with Chen et al. [54], it was noted that drug
manufacturers sponsored a majority of published analyses. Studies
not supported by the drug manufacturers were considerably less
favorable to COX-2-selective NSAIDs. Longer follow-up is neededto allow a clearer understanding of adverse event rates and their
associated outcomes.
In some cases, it was noted that the different payer perspec-
tives used in the studies could affect the interpretation of the
results. So, by example, in the study of Marshall et al. [92],
oxycodone was cost-effective compared with oxycodone–acetami-
nophen from the societal perspective, but probably not from the
healthcare perspective. The working group therefore recommends
using a 3-step approach, capturing (a) the cost of intervention,
(b) all healthcare costs, and (c) societal costs, and attempt to
illustrate each of these on the same cost-effectiveness plane.Discussion and conclusions
From this short review and the expert discussion, it is apparent
that OA is a growing problem in Western societies. Recent epide-
miological research suggests that, for individuals of 60 years of age
or older, the prevalence of symptomatic OA is about 10% for knee OA
and 5–7% for hip OA, but these levels could increase in the future
because of the increasing rates of obesity and longevity [1,2].
OA is associated with higher risk of QoL decline, comorbidity,
and death. It is associated with productivity losses in individuals
who are gainfully employed, and with the socioeconomic demands
to increase the retirement age, the burden of this productivity loss
will rise. The direct costs associated with OA are high and mostly
driven by the cost of surgery and hospitalization. The actual costs
remain challenging to measure because of the high variability of
cost estimates and the different pricing structures (as illustrated by
the recent US study requesting bundled prices for THA).
The inference that OA constitutes a considerable burden of
illness on western societies is not new (e.g. [101,102]), but is
supported by numerous recent HE studies with rigorous meth-
odological approaches. In particular, the burden of the disease in
Europe has been addressed, with more consensual diagnosis
criteria and consistent methodological approaches.
In view of these epidemiologic and economic pressures, there is
a growing urgency for more effective treatments for OA: both
symptomatic treatments, which are safe over the long-term, and
disease-modifying treatments, which could slow or halt disease
progression. It is also important to promote non-pharmacological
approaches, already adopted by guidelines, to help patients bring
about beneﬁcial lifestyle changes. For each of these approaches, it
is necessary to ﬁnd the most cost-effective options and, eventually,
identify optimal combinations of these options.
The HE studies that were reviewed and discussed during this
meeting showed considerable heterogeneity in terms of methodology
and reporting, which seriously undermines their usefulness in meta-
analyses and understanding the reasons for outcome differences. The
variety of methodological approaches is a short-coming that has been
recognized before. In 2002, an article published under the auspices of
the Outcome Measures in Rheumatology (OMERACT) and the Inter-
national League Against Rheumatism (ILAR) [103] warned against the
“lack of agreement on methods” considering it to be a “threat to the
validity, usability, and comparability of such [economic] research and
[having] major implications on regulatory decisions.” Although sev-
eral guidelines on the subject are available (ISPOR, OARSI, etc.;
[104,105]), it seems that their advice goes unheeded.
As recommended previously [103,106,107], the present working
group was strongly supportive of the development of a reference
case for HE studies in OA, i.e. a “core set” of minimum criteria that
should be included to allow comparability across studies. But, in
addition to this, the present working group advocated that the
“standard optimal care” be more clearly deﬁned, in terms of best
clinical practice, for the control arms of interventional studies.
Such an optimal care guideline would have to integrate stage of the
Table 2
Summary details of cost-effectiveness and cost–utility of pharmacological treatments in osteoarthritis
Reference and
country
Model Outcome measure(s) Intervention Results
Kamath et al.
[88] (USA)
Decision tree GI adverse events/patients
who achieved perceptible
relief pain
Rofecoxib and celecoxib vs. high-dose
acetaminophen or ibuprofen with or
without misoprostol
In average-risk population, acetaminophen dominates the
other options in terms of cost per GI event averted
In high-risk patients (for GI events) and those who do not
respond to acetaminophen, rofecoxib dominates
ibuprofen
Maetzel et al.
[85] (Canada)
Markov Quality-adjusted life years
(QALY)
Rofecoxib vs. with naproxen and celecoxib
vs. with ibuprofen and diclofenac
For patients with RA at average risk, both rofecoxib and
celecoxib are not cost-effective. In high-risk patients,
they are cost-effective
Spiegel et al. [89]
(USA)
Decision tree QALY Rofexocib and celecoxib (coxibs) vs.
naproxen
US$ 275,809 per QALY in average-risk patients
US$ 55,803 per in patients with a history of bleeding
ulcers
Moore et al. [90]
(UK)
Decision tree QALY Etoricoxib vs. non-selective NSAIDs Cost saving over non-selective NSAIDs used with a PPI or
misoprostol
£12,466 per QALY vs. non-selective NSAIDs alone
£6438 per QALY vs. NSAIDs co-prescribed with H2
antagonists
Yen et al. [91]
(Taiwan)
Decision tree QALY Celecoxib vs. naproxen US$ 21,226 per QALY
Hyaluronan vs. celecoxib US$ 42,000 per QALY
Marshall et al.
[92] (Canada)
Trial-based
economic
evaluation
QALY Oxycodone vs. oxycodone–acetaminophen Dominant (societal perspective)
US$ 75,810 per QALY (healthcare perspective)
Loyd et al. [87]
(Canada)
Decision tree QALY Celecoxib vs. NSAIDs US$ 31,097 per QALY (base model)
Ward et al. [93]
(Germany)
Discrete-
event
simulation
QALY OROS hydromorphone vs. oxycodone €8343 per QALY
Al et al. [94]
(Netherlands)
Decision tree Life year gained (LYG) NSAIDs, arthrotec and celecoxib For arthrotec compared to NSAIDs alone, €5676 per LYG
for all patients and € 526 for medium- to high-risk
patients
For celecoxib vs. arthrotec, from €56,667 to €15,429
according to pat risk
Contreras-
Hernandez
et al. [95]
(Mexico)
Decision tree Number of patient with pain
control without adverse
events
Celecoxib, non-selective NSAIDs, and
acetaminophen
Celexocib was dominant
Bessette et al.
[96] (Canada)
Markov
model
QALY Celecoxib (ﬁrst-, second-, and third-line) Second-line celecoxib was dominant
Black et al. [86]
(UK)
Cohort
simulation
QALY Glucosamine sulfate/hydrochloride and
chondroitin sulfate
£21,335 per QALY for adding glucosamine sulfate to
current care
Latimer et al.
[97] (England
and Wales)
Markov
model
QALY COX-2-selective inhibitors and traditional
NSAIDs alone or in combination with PPI
ICER less than £1000 for the addition of a PPI to both COX-
2-selective inhibitors and traditional NSAIDs
Bruyère et al.
[98] (Belgium)
Trial-based
economic
evaluation
QALY Chondroitin sulfate vs. placebo €12,984–20,866 per QALY
Scholtissen et al.
[99] (Belgium)
Trial-based
economic
evaluation
QALY Glucosamine sulfate vs. paracetamol Dominant
Glucosamine sulfate vs. placebo €3617 per QALY
Brereton et al.
[100] (UK)
Cohort
simulation
QALY Celecoxib plus a PPI vs. diclofenac plus a
PPI
£9377 per QALY
GI, gastro-intestinal; OA, osteoarthritis; PPI, proton pump inhibitor; QALY, quality-adjusted life-year; RA, rheumatoid arthritis; vs., versus.
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pharmacological approaches) and would have to be joint speciﬁc
(knee, hip, and hand). It is recognized however that due to the
large number of treatment options and relatively poor evidence of
their efﬁcacy in combination, the task is considerable [108]. Be that
as it may, the goal of being able to deﬁne a reference treatment
would facilitate the development of any new treatment and
provide a robust comparator for future meta-analysis.
In order to ﬁnd a consensus for this task, it was strongly
encouraged that the Grading of Recommendations Assessment,
Development, and Evaluation (GRADE) process [109] be followed
to evaluate studies in the ﬁeld and evaluate their outcomes and
quality of evidence. This process differs from other assessment
methods in that it “evaluates the evidence across studies for
conﬁdence in effect for each outcome and separates out judgments
about the quality of the evidence from judgments about the
importance of the recommendation” [110].The evaluation of published articles was also an area of concern
for the expert group. It was often noted that important information
was missing from the abstracts of reviewed articles and in some
cases, useful data was also missing from the body of the article. One
step toward better reporting has been takenwith the publication of
CHEERS statement [111]. Similar to the “CONSORT” statement for
randomized controlled trials, this initiative provides a checklist of
items to include when reporting economic assessments of health
interventions. Efforts are also needed to promote the use of guide-
lines used to evaluate and grade published studies [70,112].
At the present time, the treatments for OA concern essentially
pain relief. If disease-modifying OA drugs (DMOADs) could be
developed in the future [113,114], then it is possible they could
dominate HE evaluations. But these treatments are likely to be
expensive and may not work for everyone. The clinical questions
will then become, in which patients do these provide the most
beneﬁt and at what stage of OA progression they should be used.
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action of the DMOAD and the biomarkers associated with and
radiographic characteristics of the diseased joint. The second
question, the problem of staging in OA, continues to provoke
debate. The lack of a hard clinical end point (and a probabilistic
model of attaining that endpoint) is one of the main differentiating
factors in the economic research on OA compared with osteopo-
rosis (OP). Although the ﬁnal outcome of HE is the QALY gain/loss
over lifetime, it can be informative to assess differences at an
intermediate endpoint. Thus, to be able to capture QALY gain/
difference at the “time of treatment failure” should be investigated
and included in new analytical models.
The surrogate endpoint in OA of “time to treatment failure” or
“need for joint replacement surgery” based on the structural
changes and symptomatic thresholds has been proposed previously
[115,116], but due to regional differences as to when to perform
surgery and the inconsistencies in the decision process, this
proposition has still to convince the clinical opinion leaders [14].
Due to the major cost implications of TJA, delaying such a step
(where possible) has a signiﬁcant effect on health budgets.
Furthermore, because most TJA are elective procedures and the
utilization of elective surgery is likely to increase, it has been
argued that the development of appropriateness criteria to deter-
mine priorities will provide a powerful tool for controlling costs
[117,118]. The use of a validated surrogate endpoint could also
prove critical for the development of DMOADs. Thus, economic
models of OA will, in the future, have to integrate the possibilities
of structural modiﬁcation and intermediate endpoints. It will also
be necessary to address the question of whether by prolonging the
time to arthroplasty, the success of this intervention (in terms of
recovery time, QOL, revision, etc.) is negatively impacted.
In conclusion, OA is a common disease with high prevalence in
later life. Although the prevalence rates vary widely across studies,
due to differences in diagnostic criteria and populations, some clear
patterns are beginning to emerge. One is the increasing risk in
overweight individuals, whereas others are the relatively greater risk
in older women than men and the increasing prevalence in younger
age groups of both sexes (particularly the 50–59 years of age). The
growing demand for elective surgery for joint replacement, partic-
ularly from relatively younger age groups, drives the need for more
long-lasting prostheses and increases the risk of surgical revision.
Even within the traditional population base, the costs of treatment
(driven mainly by joint replacement) are rising steadily and pose a
considerable cost burden onwelfare states. Current treatments, which
comprise pharmacological and non-pharmacological therapies, aim to
reduce pain and maintain functional performance, but they are not
always good value for money. But HE studies conducted in the ﬁeld
fail to allow ready comparison, and few hard conclusions can be
drawn. Previously issued guidelines and reference case analysis for HE
studies appear to go largely unheeded. The working group concluded
that the development of a consensus on standard optimal care of OA
patients (according to stage and affected joint) would greatly help in
assuring comparability between studies and support the reference
case. This and the ﬁne-tuning of the concepts of “time to treatment
failure” or “time to arthroplasty”will assist the regulatory pathway for
future disease-modifying drugs. Thus, there remains much to be done
in terms of providing clinical guidelines for treating OA as well as
promoting the use of existing methodological guidelines for the
conduct of HE studies before we can be certain of the real incremental
cost-effectiveness between existing treatment options.Conﬂicts of interest
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